MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: Interaction with clinical outcome

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Medimegh, Imen ^a   Omrane, Ines ^a   Privat, Maud ^c   Uhrhummer, Nancy ^c   Ayari, Hajer ^a   Belaiba, Fadoua ^a   Benayed, Farhat ^b   Benromdhan, Khaled ^b   Mader, Sylvie ^d   Bignon, Ives Jean ^c   Elgaaied, Amel Benammar ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b SALAH AZAIEZ INSTITUTE   (Tunisia)

^c CENTRE JEAN PERRIN   (France)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 10B; MICRORNA 146A; MICRORNA 148A; MICRORNA 17; MICRORNA 182; MICRORNA 21; MICRORNA 34A; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MEDICAL HISTORY; ORAL CONTRACEPTIVE USE; POLYMERASE CHAIN REACTION; RNA ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; CARCINOMA, DUCTAL, BREAST; GENE EXPRESSION; GENETICS; METABOLISM; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TRIPLE NEGATIVE BREAST NEOPLASMS; TUNISIA;

ADULT; BIOMARKERS, TUMOR; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION; HUMANS; MICRORNAS; PROGNOSIS; ROC CURVE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUNISIA;

EID: 84929642309     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111877     Document Type: Article

References (48)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
2. Leidy J, Khan A, Kandil D (2014) Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features. Arch Pathol Lab Med 138: 37-43.
3. Knoop AS, Laenkholm AV, Jensen MB, Nielsen KV, Andersen J, et al. (2014) Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Eur J Cancer 50: 1412-1421.
4. Maly JJ, Macrae ER (2014) Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival. Breast Cancer (Auckl) 8: 81-88.
5. Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, et al. (2012) Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 133: 713-723.
6. Vormoor B, Curtin NJ (2014) Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma. Curr Opin Oncol.
7. Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, et al. (2014) High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol.
8. Montero JC, Esparis-Ogando A, Re-Louhau MF, Seoane S, Abad M, et al. (2014) Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene 33: 148-156.
9. Jaitak V (2014) Drug Target Strategies in Breast Cancer Treatment: Recent Developments. Anticancer Agents Med Chem.
10. Niemiec JA, Adamczyk A, Ambicka A, Mucha-Malecka A, W MW, et al. (2014) Triple-negative, basal marker-expressing, and high-grade breast carcinomas are characterized by high lymphatic vessel density and the expression of podoplanin in stromal fibroblasts. Appl Immunohistochem Mol Morphol 22: 10-16.
11. Bagaria SP, Ray PS, Sim MS, Ye X, Shamonki JM, et al. (2014) Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg 149: 125-129.
12. Andres R, Pajares I, Balmana J, Llort G, Ramon YCT, et al. (2014) Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). Clin Transl Oncol 16: 280-284.
13. Williams CK, Cristina Stefan D, Rawlinson F, Simbiri K, Mbulaiteye SM (2014) The African Organisation for Research and Training in Cancer and its conferences: A historical perspective and highlights of the Ninth International Conference, Durban, South Africa, 21-24 November 2013. Ecancermedicalscience 8: 396.
14. Christodoulatos GS, Dalamaga M (2014) Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? World J Clin Oncol 5: 71- 81.
15. Subtil FS, Wilhelm J, Bill V, Westholt N, Rudolph S, et al. (2014) Carbon ion radiotherapy of human lung cancer attenuates HIF-1 signaling and acts with considerably enhanced therapeutic efficiency. FASEB J 28: 1412-1421.
16. Nugent M (2014) MicroRNA function and dysregulation in bone tumors: the evidence to date. Cancer Manag Res 6: 15-25.
17. Puppin C, Durante C, Sponziello M, Verrienti A, Pecce V, et al. (2014) Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. Endocrine.
18. Piva R, Spandidos DA, Gambari R (2013) From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol 43: 985-994.
19. Shah MY, Calin GA (2014) MicroRNAs as therapeutic targets in human cancers. Wiley Interdiscip Rev RNA 5: 537-548.
20. Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, et al. (2011) MicroRNA signatures differentiate melanoma subtypes. Cell Cycle 10: 1845-1852.
21. Volinia S, Croce CM (2013) Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A 110: 7413-7417.
22. Jiang F, Mu J, Wang X, Ye X, Si L, et al. (2014) The Repressive Effect of miR- 148a on TGF beta-SMADs Signal Pathway Is Involved in the Glabridin- Induced Inhibition of the Cancer Stem Cells-Like Properties in Hepatocellular Carcinoma Cells. PLoS One 9: e96698.
23. Varendi K, Kumar A, Harma MA, Andressoo JO (2014) miR-1, miR-10b, miR- 155, and miR-191 are novel regulators of BDNF. Cell Mol Life Sci.
24. Zhu K, Pan Q, Zhang X, Kong LQ, Fan J, et al. (2013) MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis 34: 2071-2079.
25. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sanudo A, et al. (2013) MicroRNA expression profiles in the progression of prostate cancer-from highgrade prostate intraepithelial neoplasia to metastasis. Urol Oncol 31: 796-801.
26. Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlback B (2014) The miR ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer.
27. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688.
28. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E (2009) MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 125: 1407-1413.
29. Tang J, Ahmad A, Sarkar FH (2012) The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis. Int J Mol Sci 13: 13414-13437.
30. Chou WW, Wang YT, Liao YC, Chuang SC, Wang SN, et al. (2013) Decreased microRNA-221 is associated with high levels of TNF-alpha in human adipose tissue-derived mesenchymal stem cells from obese woman. Cell Physiol Biochem 32: 127-137.
31. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
32. Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, et al. (2014) Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol.
33. Huang TH, Wu F, Loeb GB, Hsu R, Heidersbach A, et al. (2009) Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem 284: 18515-18524.
34. Petrovic N, Mandusic V, Dimitrijevic B, Roganovic J, Lukic S, et al. (2014) Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia. Med Oncol 31: 977.
35. Gao J, Zhang Q, Xu J, Guo L, Li X (2013) Clinical significance of serum miR- 21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res 25: 743-748.
36. Pastrello C, Polesel J, Della Puppa L, Viel A, Maestro R (2010) Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2- negative familial breast and ovarian cancer patients. Carcinogenesis 31: 2124- 2126.
37. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, et al. (2011) Downregulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 3: 279-290.
38. Wang J, Wang Q, Liu H, Shao N, Tan B, et al. (2012) The association of miR- 146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk: A meta-analysis of 32 studies. Mutagenesis 27: 779-788.
39. Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay MA (2008) Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans 36: 1211-1215.
40. Kumar S, Keerthana R, Pazhanimuthu A, Perumal P (2013) Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. Indian J Biochem Biophys 50: 210-214.
41. Korlimarla A, Prabhu JS, Remacle J, Raja U, Srinath BS, et al. (2014) 23p ∗ alternate epigenetic mechanism for the repression of brca1 in sporadic breast cancers mediated by mir182. Ann Oncol 25 Suppl1: i9.
42. McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, et al. (2012) Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma. Mod Pathol 25: 1644-1653.
43. Hardell E, Carlberg M, Nordstrom M, van Bavel B (2010) Time trends of persistent organic pollutants in Sweden during 1993-2007 and relation to age, gender, body mass index, breast-feeding and parity. Sci Total Environ 408: 4412-4419.
44. Vorherr H (1979) Pregnancy and lactation in relation to breast cancer risk. Semin Perinatol 3: 299-311.
45. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, et al. (2007) A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867.
46. Gokhale A, Kunder R, Goel A, Sarin R, Moiyadi A, et al. (2010) Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther 6: 521-529.
47. Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, et al. (2014) Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev 23: 755-764.
48. Elebro K, Butt S, Dorkhan M, Jernstrom H, Borgquist S (2014) Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmo Diet and Cancer Cohort. Cancer Causes Control.